Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Evommune, Inc.NYSE: EVMN
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) rises 573.5% from a year ago
Property, plant & equipment (net) stood at $9.57M at the end of Q1 FY2026, up 573.5% from a year earlier and up 288.6% from the prior quarter.
Context
- Property, plant & equipment (net) amounted to 3.0% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps rising in the next quarterly balance sheet after a +573.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 2.46M USD
- Year-over-year change
- +37.0%
- 2-year CAGR
- +12.0%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.46M | +37.0% |
| FY2024 | 2024-12-31 | 1.8M | -8.5% |
| FY2023 | 2023-12-31 | 1.97M | — |
Property, Plant & Equipment (Net) vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 property, plant & equipment (net) of $9.57M is the 7th highest of the 10 companies compared; the peer median is $19.78M.
- Its year-over-year change of +573.5% is the highest of 10, against a peer median of -21.6%.
- Property, plant & equipment (net) amounts to 3.0% of total assets for EVMN, versus a peer median of 5.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $156.2M | +5.0% | -3.2% | 5.8% |
| Sep 2026 | $63.5M | +95.6% | — | 5.4% | |
| Mar 2026 | $42.15M | -3.7% | -11.1% | 32.6% | |
| Mar 2026 | $24.07M | -24.7% | -15.5% | 8.2% | |
| Mar 2026 | $19.78M | -33.1% | +39.8% | 6.9% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $16.3M | -21.6% | -14.3% | 15.4% |
EVMNEvommune, Inc. | Mar 2026 | $9.57M | +573.5% | — | 3.0% |
| Jun 2026 | $6.44M | -44.6% | -26.8% | 0.3% | |
| Mar 2026 | $4.5M | -22.4% | -14.2% | 3.4% | |
CLYMClimb Bio, Inc. | Mar 2026 | $697K | +54.5% | +19.0% | 0.5% |
| Peer median (excluding EVMN) | $19.78M | -21.6% | -12.7% | 5.8% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.